The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens

被引：42

作者：

MacGowan, A ^{[1
]}

Rogers, C

Bowker, K

机构：

[1] N Bristol NHS Trust, Bristol Ctr Antimicrobial Res & Evaluat, Bristol BS10 5NB, Avon, England

[2] Univ Bristol, Dept Med Microbiol, Southmead Hosp, Bristol BS10 5NB, Avon, England

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2000年 / 46卷 / 02期

关键词：

D O I：

10.1093/jac/46.2.163

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

[No abstract available]

引用

页码：163 / 170

页数：8

共 49 条

[1]

AESCHLIMANN JR, 1998, 38 INT C ANT AG CHEM, P12

[2] QUESTIONING DOSING REGIMENS OF CIPROFLOXACIN [J].

BAUERNFEIND, A .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 (05) :789-798

[3]

Bauernfeind A., 1999, Journal of Antimicrobial Chemotherapy, V43, P77, DOI 10.1093/jac/43.suppl_3.77

[4]

BAUERNFEIND A, 1994, CIPROFLOXACIN 1, V5, P37

[5]

BAUERNFEIND A, 1998, ANTIINFECTIVE DR S71, V16, pT135

[6] COMPARATIVE-STUDY WITH ENOXACIN AND NETILMICIN IN A PHARMACODYNAMIC MODEL TO DETERMINE IMPORTANCE OF RATIO OF ANTIBIOTIC PEAK CONCENTRATION TO MIC FOR BACTERICIDAL ACTIVITY AND EMERGENCE OF RESISTANCE [J].

BLASER, J ;

STONE, BB ;

GRONER, MC ;

ZINNER, SH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (07) :1054-1060

[7] IN-VIVO VERIFICATION OF IN-VITRO MODEL OF ANTIBIOTIC-TREATMENT OF DEVICE-RELATED INFECTION [J].

BLASER, J ;

VERGERES, P ;

WIDMER, AF ;

ZIMMERLI, W .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (05) :1134-1139

[8]

Bowker Karen E., 1999, Journal of Antimicrobial Chemotherapy, V44, P58

[9] Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin [J].

Bowker, KE ;

Wootton, M ;

Rogers, CA ;

Lewis, R ;

Holt, HA ;

MacGowan, AP .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (05) :661-667

[10]

BOWKER KE, 1998, 38 INT C ANT AG CHEM, P229

← 1 2 3 4 5 →